Skip to main content

Moberg Pharma announces prospectus regarding admission to trading of new shares

Not for announcement, publication or distribution, directly or indirectly, in or into the U.S., Canada, Japan, Hong Kong, New Zealand, South Africa or Australia. 

The prospectus regarding the admission to trading of newly issued shares in Moberg Pharma AB (publ) is now available on the company’s website and in the company’s offices, at Gustavslundsvägen 42, 167 51 Bromma. Documents incorporated by reference in the prospectus are also available in accordance with the above.

The prospectus has been prepared due to the admission to trading of the 2,068,965 new shares in Moberg Pharma, that were issued in connection with the directed share issue to a limited group of Swedish and international institutional qualified investors, which was resolved upon on May 27, 2014. The newly issued shares are expected to be admitted to trading on NASDAQ OMX Stockholm on or about June 18, 2014.

For further information, please contact:
Peter Wolpert, CEO

Mobile: +46 (0)70 - 735 71 35

Peter Östling, IR 
Mobile: +46 (0)76 – 314 09 78

About this information
The information provided herein is such that Moberg Pharma is required to disclose pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 08.30 am (CET) on June 18, 2014

Important information
Publication or distribution of this press release in certain jurisdictions may be subject to restrictions according to law and the people in jurisdictions where this press release has been made public or distributed should inform themselves and follow such local restrictions. This press release does not contain and does not constitute or form part of an invitation to acquire or subscribe or a solicitation of any offer to buy or subscribe for shares, subscription rights or other securities in Moberg Pharma.

This press release may not be published or distributed, directly or indirectly, in or into the U.S., Canada, Japan, Hong Kong, New Zealand, South Africa, Australia or in any other jurisdiction where such distribution would be prohibited by applicable law. The information in this press release may not be redistributed, reproduced or passed on in ways that conflict with applicable restrictions. Failure to comply with these restrictions may constitute a violation of the United States Securities Act of 1933 (“Securities Act”) or applicable laws of other jurisdictions

About Moberg Pharma
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with a direct sales and marketing organization in the U.S. and an extensive distributor network in more than 40 countries. The company’s OTC portfolio includes the brands Kerasal®, Jointflex®, Kerasal Nail™, Domeboro®, Vanquish®, and Fergon®. Kerasal Nail™ (Nalox™ in certain ex-U.S. markets) is the leading product for the treatment of nail disorders in the U.S. and Nordic market. The current portfolio will be supplemented by the acquisition and in-licensing of additional products as well as product development with a focus on innovative drug delivery of proven compounds. Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares (OMX: MOB) are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: